文献速递脑血管病

pRESET与Solitaire支架取栓器作为大血管闭塞性卒中一线治疗的随机临床试验

Thrombectomy With the pRESET vs Solitaire Stent Retrievers as First-Line Large Vessel Occlusion Stroke Treatment: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2024-01-01

这项多中心、前瞻性、随机、对照、开放标签、适应性、非劣效性试验纳入340例大血管闭塞性卒中患者,比较pRESET与Solitaire支架取栓器。90天功能独立率pRESET组为54.9%,Solitaire组为57.5%,绝对差异-2.57%(95%CI,-11.42至6.28),因95%CI下限大于-12.5%,判定pRESET非劣效于Solitaire。

要点

  • pRESET组90天功能独立率54.9%,Solitaire组57.5%,绝对差异-2.57%(95%CI,-11.42至6.28)。
  • 因95%CI下限大于-12.5%非劣效界值,pRESET支架取栓器被判定非劣效于Solitaire支架取栓器。
  • 症状性颅内出血pRESET组0例,Solitaire组2例(1.2%);90天死亡率分别为14.5%和14.4%。

核心结论

  • 在大血管闭塞性卒中患者中,pRESET支架取栓器取栓非劣效于Solitaire支架取栓器取栓。
  • 研究结果提示pRESET为大血管闭塞性卒中患者的血流恢复和残疾减轻提供了安全有效的选择。

研究设计与样本

  • 多中心、前瞻性、随机、对照、开放标签、适应性、非劣效性试验,主要终点评估采用盲法。
  • 2019年10月至2022年2月期间,在美国19家研究医院和/或大学以及德国5家机构开展。
  • 纳入症状发作后8小时内的大血管闭塞性卒中患者,共随机340例,其中女性170例(50.0%),中位(IQR)年龄73.0(64.0-82.0)岁。
  • 患者按1:1随机接受pRESET或Solitaire支架取栓器取栓治疗。

主要发现

  • 90天功能独立主要终点pRESET组95例(54.9%;95%CI,48.7-61.1)达成,Solitaire组96例(57.5%;95%CI,51.2-63.8),绝对差异-2.57%(95%CI,-11.42至6.28)。
  • 3次取栓内eTICI评分2b50或以上pRESET组146/173例(84.4%),Solitaire组149/167例(89.2%),绝对差异-4.83%(95%CI,-10.84至1.19)。
  • 首次取栓后eTICI评分2c或以上pRESET组76/173例(43.7%),Solitaire组74/167例(44.3%),绝对差异-0.63%(95%CI,-9.48至8.21)。
  • 症状性颅内出血pRESET组0例,Solitaire组2例(1.2%)。
  • 90天死亡率pRESET组25例(14.5%),Solitaire组24例(14.4%)。

关键数值与推荐

  • 非劣效性界值为pRESET与Solitaire取栓器差异的单侧95%CI下限-12.5%。
  • 因95%CI下限-11.42%大于-12.5%,pRESET被判定非劣效于Solitaire。
  • 次要临床终点(90天改良Rankin量表评分移位)和两项血管造影终点也观察到pRESET非劣效于Solitaire。
  • 符合方案分析和按治疗分析结果与意向性治疗分析结果一致。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Stent retriever-based thrombectomy is highly beneficial in large vessel occlusion (LVO) strokes. Many stent retriever designs are currently available, but comparison of these technologies in well-conducted studies is lacking. OBJECTIVE: To determine whether thrombectomy for LVO stroke with the pRESET stent retriever is noninferior to treatment with the Solitaire stent retriever. DESIGN, SETTING, AND PARTICIPANTS: This study was a multicenter, prospective, randomized, controlled, open-label, adaptive, noninferiority trial with blinded primary end point evaluation. Between October 2019 and February 2022, multicenter participation occurred across 19 research hospitals and/or universities in the US and 5 in Germany. Patients with LVO stroke were enrolled and included up to 8 hours after symptom onset. INTERVENTIONS: Patients underwent 1:1 randomization to thrombectomy with the pRESET or Solitaire stent retriever. MAIN OUTCOMES AND MEASURES: The primary outcome was the difference in the rate of 90-day functional independence across the 2 devices, using a -12.5% noninferiority margin for the lower bound of the 1-sided 95% CI of the difference between pRESET and Solitaire retrievers. RESULTS: Of 340 randomized patients, 170 (50.0%) were female, and the median (IQR) age was 73.0 (64.0-82.0) years. The study procedure was completed in 322 of the 340 randomized patients. The primary end point of 90-day functional independence was achieved by 95 patients (54.9%; 95% CI, 48.7-61.1) in the pRESET group and in 96 (57.5%; 95% CI, 51.2-63.8) in the Solitaire group (absolute difference, -2.57%; 95% CI, -11.42 to 6.28). As the lower bound of the 95% CI was greater than -12.5%, the pRESET retriever was deemed noninferior to the Solitaire retriever. The noninferiority of pRESET over Solitaire was also observed in the secondary clinical end point (90-day shift in modified Rankin Scale score) and in both angiographic end points (Expanded Treatment in Cerebral Infarction [eTICI] score of 2b50 or greater within 3 passes: 146 of 173 [84.4%] vs 149 of 167 [89.2%]; absolute difference, -4.83%; 95% CI, -10.84 to 1.19; eTICI of 2c or greater following the first pass: 76 of 173 [43.7%] vs 74 of 167 [44.3%]; absolute difference, -0.63%; 95% CI, -9.48 to 8.21). Symptomatic intracranial hemorrhage occurred in 0 patients in the pRESET group and 2 (1.2%) in the Solitaire group. Mortality occurred in 25 (14.5%) in the pRESET group and in 24 (14.4%) in the Solitaire group at 90 days. Findings of the per-protocol and as-treated analyses were in concordance with findings of the intention-to-treat analysis. CONCLUSIONS AND RELEVANCE: In this study, among patients with LVO stroke, thrombectomy with the pRESET stent retriever was noninferior to thrombectomy with the Solitaire stent retriever. Findings suggest that pRESET offers a safe and effective option for flow restoration and disability reduction in patients with LVO stroke.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Nogueira RG, Lobsien D, Klisch J, et al. Thrombectomy With the pRESET vs Solitaire Stent Retrievers as First-Line Large Vessel Occlusion Stroke Treatment: A Randomized Clinical Trial. JAMA Neurol. 2024. PMID: 38165690. doi:10.1001/jamaneurol.2023.5010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。